Literature DB >> 3495442

Effect of stereospecificity of chemically synthesized lipid A-subunit analogues GLA-27 and GLA-40 on the expression of immunopharmacological activities.

Y Kumazawa, S Ikeda, H Takimoto, C Nishimura, M Nakatsuka, J Y Homma, A Yamamoto, M Kiso, A Hasegawa.   

Abstract

Tumor necrosis factor (TNF)-inducing, mitogenic, polyclonal B cell activation (PBA), macrophage activation and antiviral activities of chemically synthesized lipid A-subunit analogues, GLA-27 and GLA-40, were investigated. The structure of GLA-27 comprises 4-O-phosphono-D-glucosamine carrying tetradecanoyl and 3-tetradecanoyloxytetradecanoyl [C14-O-(C14)] groups as the 3-O- and 2-N-acyl substituents, respectively. GLA-40 is a 1-deoxy compound of GLA-27. The activities of stereoisomers, (R) and (S) forms at the C3 position of the C14-O-(C14) group, of both compounds were also investigated. TNF-inducing activity of the (S) isomers of GLA-27 and GLA-40 was stronger than that of the (R) isomers while the (R) isomers exhibited stronger mitogenic and PBA activities than the (S) isomers. With respect to macrophage activation such as phagocytosis, acid phosphatase and N-acetyl-beta-D-glucosaminidase activity as cellular lysosomal enzymes and cytostasis, peritoneal macrophages obtained from mice administered i.p. with test samples showed significant activities. Among stereoisomers of GLA-27, the (R) isomer exhibited somewhat stronger phagocytic and lysosomal enzyme activities than those of the (S) isomer while there was no appreciable difference in the activities between the isomers of GLA-40. Significant cytostasis-inducing activity was observed in stereoisomers tested. All of the isomers showed remarkable antiviral activity against vaccinia virus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495442     DOI: 10.1002/eji.1830170513

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Immunopharmacological activities of 2-keto-3-deoxyoctonic acid-(alpha 2----6)-linked 4-O-phosphono-D-glucosamine derivatives carrying N- and 3-O-acyl substituents.

Authors:  Y Kumazawa; M Matsuura; J Y Homma; T Furuya; H Takimoto; K Inagaki; T Nagumo; M Kiso; A Hasegawa
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

2.  Enhancement of immunoglobulin G responses in mice against hepatitis B virus surface antigen, influenza virus hemagglutinin vaccine, and tetanus toxoid by 6-O-acylated muramyl dipeptides.

Authors:  T Furuya; Y Kumazawa; H Takimoto; T Nagumo; M Watanabe; C Aizawa; M Kiso; A Hasegawa; K Nomoto
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

3.  Induction of an endogenous tumor necrosis factor in mice by murine recombinant interferon-gamma combined with a lipid A subunit analog (GLA-60) of low toxicity.

Authors:  I Saiki; H Maeda; T Sakurai; J Murata; J Iida; M Kiso; A Hasegawa; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Thy 1+ asialo GM1+ dendritic epidermal cells in skin defense mechanisms of vaccinia virus-infected mice.

Authors:  S Ikeda; T Tominaga; C Nishimura
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity.

Authors:  Y Kumazawa; M Nakatsuka; H Takimoto; T Furuya; T Nagumo; A Yamamoto; Y Homma; K Inada; M Yoshida; M Kiso
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

6.  Cyclic AMP inhibition of lipopolysaccharide-induced restriction of Legionella pneumophila growth in macrophage cultures.

Authors:  K Egawa; T W Klein; Y Yamamoto; C A Newton; H Friedman
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

7.  DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice.

Authors:  K Sato; I Saiki; Y C Yoo; Y Igarashi; M Kiso; A Hasegawa; I Azuma
Journal:  Jpn J Cancer Res       Date:  1992-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.